Elysium Basis Review: Is the Premium NR Worth the Price?

Elysium Basis is one of the few NAD+ supplements that earns a serious, evidence-based review rather than a dismissal. Unlike most of the category — where "clinically studied" means a single trial on a different compound — Basis has a dedicated human trial on its exact formulation, third-party purity certification, and a company built around academic credibility. That's rare, and it's real. But "legitimate and well-made" is not the same as "worth $480–720 a year," and this review keeps those two questions separate: what Basis genuinely delivers (a reliable NAD+ increase, verified safety, clean third-party testing) versus what it does not (any proven health outcome — and a value case that survives the price tag).

What Elysium Basis is

Basis is the flagship product of Elysium Health, a company founded with an unusually strong science-advisory roster. Each daily two-capsule serving pairs 250 mg of nicotinamide riboside (NR) — a vitamin-B3-derived NAD+ precursor — with 50 mg of pterostilbene, a polyphenol chemically related to resveratrol. The pitch is that NR raises NAD+ while pterostilbene acts as a "sirtuin-activating" partner that makes the combination work harder than NR alone.

Two things set Basis apart from generic NR and NMN brands and justify reviewing it on its own terms. First, the specific NR-plus-pterostilbene blend (which Elysium calls NRPT) has been through its own placebo-controlled human trial — not a stand-in. Second, Basis is NSF Certified for Sport, a respected third-party certification that verifies label accuracy and screens for banned substances and contaminants. In a category notorious for products that under-deliver on what's printed on the bottle, that certification is a genuine quality signal. Just be clear about what it certifies: purity and label honesty, not that the product produces any health benefit.

Does Basis raise NAD+? Yes — and it has its own trial to prove it

Start with the strongest claim, because it holds. NR is the rare oral NAD+ precursor with replicated human pharmacokinetic data: a foundational 2016 study established that NR is uniquely and orally bioavailable in humans, raising blood NAD+ after dosing ¹, and a 2018 randomized trial confirmed chronic NR is well tolerated and elevates NAD+ in healthy middle-aged and older adults ².

But Basis doesn't have to borrow those results, because it has its own. A 2017 randomized, double-blind, placebo-controlled study of NRPT — the exact Basis formulation — found that repeat dosing raised whole-blood NAD+ by roughly 40% at the recommended dose, sustainably and safely over eight weeks ³. That trial was company-run (its authors include Elysium-affiliated researchers), which is worth flagging for transparency — but it is a real, peer-reviewed, placebo-controlled result on the actual product, which is more than almost any competitor can say. A later independent hospital trial of the same NRPT formulation in patients with acute kidney injury likewise confirmed it increases NAD+ in a clinical population ⁴, reinforcing that the NAD+-raising effect is robust and not a fluke of one study.

So on the central biochemical promise — this raises your NAD+ — Basis is well supported. If your only question is "will Basis actually increase my NAD+," the honest answer is yes, it very likely will, by roughly 40%.

The pterostilbene premium: what you're actually paying for

Here's where the review gets pointed, because pterostilbene is the entire reason Basis costs more than plain NR — and the evidence for that premium is thin.

Pterostilbene is a resveratrol-like polyphenol with interesting preclinical, antioxidant, and sirtuin-related biology. But the uncomfortable fact for the Basis pitch is this: there is no human trial showing that adding pterostilbene to NR produces a clinical outcome that NR alone does not. The pivotal NRPT study demonstrated the combination raises NAD+ safely ³ — a biomarker result — not that the pterostilbene component delivers better energy, cognition, longevity, or any felt benefit than plain NR would. No head-to-head human trial has pitted NR + pterostilbene against NR alone and shown the blend wins on any hard endpoint.

That matters for the wallet. The marginal money you spend on Basis over a plain NR product is, in evidence terms, buying an ingredient whose added benefit over NR-alone is unproven in humans. Pterostilbene isn't useless or unsafe — it's that the claim "NR + pterostilbene beats NR" rests on mechanism and marketing, not on a controlled outcome trial. For the broader pattern of polyphenol "NAD+ partner" claims outrunning the evidence, see our NAD+ and resveratrol stack analysis.

The price reality: $480–720 a year

This is the crux of the review. As of 2026, Basis typically runs around $40–60 per month depending on subscription tier and pack size — roughly $480–720 a year. By comparison, a well-made third-party-tested plain NR product commonly sells for about $20–35 a month, and generic NR or NMN can be cheaper still.

Put plainly: you can buy a reliable ~40% NAD+ increase for a fraction of what Basis charges. The Basis premium pays for three things — the dedicated NRPT trial, the NSF Certified for Sport testing, and the pterostilbene add-on. The first two are real value (research pedigree and verified purity genuinely matter in this category). The third is not demonstrated. And none of the three changes the most important fact below: that the outcome you're hoping for isn't proven for any of these products.

The part the marketing glides past: NAD+ is a biomarker, not an outcome

This framing should govern the entire decision, and it applies to Basis exactly as it does to every NAD+ precursor: raising NAD+ is not the same as improving how you feel, perform, or age — and in trial after trial, the biomarker moves while the outcome doesn't.

The clearest cautionary results come from NR's own literature. When NR augmented the aged human muscle NAD+ metabolome, it did not improve muscle bioenergetics or physical performance ⁵ — the fuel gauge rose, the engine output stayed flat. On cognition, a randomized placebo-controlled trial in older adults with mild cognitive impairment raised blood NAD+ about 2.6-fold but left neurocognitive scores unchanged ⁶. And a 2025 systematic review and meta-analysis of NR and NMN on skeletal muscle mass and function found no reliable improvement when results were pooled across trials ⁷.

NR does have one concrete, specific functional win: in the NICE randomized trial in peripheral artery disease, six months of NR produced a small but significant improvement in 6-minute walking distance (about +17.6 m between groups) ⁸. But note what that is — a specific outcome, in a specific patient population, not a general energy-or-longevity boost for a healthy buyer. The honest read for Basis: it's an NAD+ booster with a verified safety record and an unproven downstream payoff. It's a dietary supplement, not an FDA-approved drug, so it isn't approved to treat, prevent, or cure anything. For the wider context, start with our NAD+ therapy evidence pillar.

Is Elysium Basis worth it?

Put the pieces together honestly:

• •What you're reliably buying: a legitimately well-made NR supplement that raises whole-blood NAD+ ~40% ³, with a dedicated human trial and NSF Certified for Sport purity verification. Both are above the category average and genuinely worth something.
• •What you're not reliably buying: any proven improvement in energy, cognition, strength, or longevity — the downstream human benefits are modest, mixed, and largely confined to specific populations or outcomes ⁵⁶⁷. Nor are you buying a proven advantage from the pterostilbene that justifies the premium.
• •The value math: at $480–720/yr versus $20–35/mo for plain third-party-tested NR, you're paying roughly double-plus for the same well-proven NAD+ increase, the same reassuring safety, and an add-on the trials haven't shown helps.

So the fair verdict is: Basis is a legitimate, trial-backed, third-party-certified product — but a weak value. If verified purity and the comfort of a product-specific trial matter enough to you to pay the premium, it's a defensible choice. But if your goal is simply a reliable, well-documented NAD+ increase at the best price, you can get that for far less. And if you're expecting the dramatic energy or anti-aging benefits the category markets, the evidence will disappoint you — that's true of plain NR, of Basis, and of every NAD+ precursor.

For the direct cost-and-dose breakdown against the other leading NR brand, see our head-to-head Tru Niagen vs Elysium Basis, and our Tru Niagen review for the cheaper single-ingredient alternative.

Bottom line

Elysium Basis earns its reputation as a quality product: it has its own placebo-controlled trial showing a ~40% NAD+ rise ³, it's NSF Certified for Sport, and it's built by a science-credible company. What it doesn't have is a proven health outcome — raising NAD+ is a biomarker change, not a demonstrated benefit ⁵⁶ — or a pterostilbene advantage that justifies costing roughly double a plain NR product. At $480–720 a year against $20–35 a month for well-tested NR, Basis is a legitimate but hard-to-justify spend. To weigh the cheaper alternative and the whole shelf by evidence, read Tru Niagen vs Elysium Basis, the best NAD+ supplements ranking, and the NAD+ rankings hub.